Speech-Language Pathologists in Piedmont, SD Accepting Medicare

5 Speech-Language Pathologists found. Showing 1 - 5

Taylor Stephanie Erlenbusch Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 15602 Buckhorn Ct, Piedmont, SD 57769 Phone: 605-431-8946

Amanda Anne Neisner, MS, CCC/SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 13555 Frontier Loop, Piedmont, SD 57769 Phone: 605-716-9529    Fax: 605-716-9576

Heather Erlenbusch Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 16159 2nd St, Piedmont, SD 57769 Phone: 605-787-5295

Therapy Solutions Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 13555 Frontier Loop, Suite 6, Piedmont, SD 57769 Phone: 605-716-9529    Fax: 605-716-9576

Samantha Drury, MA CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 12675 Mohawk Dr, Piedmont, SD 57769 Phone: 605-431-5944

News Archive

NCI-funded SPORE grant aims to improve kidney cancer treatment

The National Cancer Institute (NCI) has awarded Beth Israel Deaconess Medical Center (BIDMC) an $11.5 million, five-year SPORE grant to focus on cancers of the kidney. Michael Atkins, MD, Deputy Director of BIDMC's Division of Hematology/Oncology, will oversee the grant, which involves collaborations with Brigham and Women's Hospital, Dana-Farber Cancer Institute, and Massachusetts General Hospital via the Dana-Farber/Harvard Cancer Center.

Study provides new estimates of opioid misuse, addiction

New estimates suggest that 20 to 30 percent of opioid analgesic drugs prescribed for chronic pain are misused, while the rate of opioid addiction is approximately 10 percent, reports a study in the April issue of PAIN, the official journal of the International Association for the Study of Pain.

Genmab reaches milestone for Arzerra under terms of collaboration with GSK

Genmab A/S announced today it has reached a milestone for Arzerra(ofatumumab) under the terms of its collaboration with GlaxoSmithKline.

Human coronaviruses cause processing body loss

Researchers continue to expand their knowledge of coronaviruses, including the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pathogen. Now, a new study published on the preprint server bioRxiv in November 2020 describes a vital mechanism whereby the novel SARS-CoV-2 pathogen can restrict the human host response. In doing so, the study explores how this novel feature of SARS-CoV-2 works and how it results in a reshaping of the human host's immune response.

Can-Fite receives EMA clearance to begin CF102 Phase II trial for treatment of HCC patients in Europe

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs being developed to treat inflammatory diseases, cancer and sexual dysfunction, today announced it recently received clearance from the European Medicines Agency to commence dosing patients in Europe in its global Phase II trial for CF102 in the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer.

Read more Medical News

› Verified 2 days ago